Walter J. Storkus

University of Pittsburgh Medical Center — United States

Immunology and Microbiology · Life Sciences

74h-index20.1kcitations465works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(286), Cancer Immunotherapy and Biomarkers(134), CAR-T cell therapy research(123), Immune Cell Function and Interaction(105), T-cell and B-cell Immunology(100)

Publications465 total

Molecular Remodeling of Peritumoral Tissue in Clear Cell Renal Cell Carcinoma: Insights into Inflammaging and Prognostic Markers
Cancers·2026Open Access
NK receptor signaling lowers the TCR activation threshold: role in selective recognition of cancer cells, but not healthy tissues, by TAA-specific CTLs 2687
The Journal of Immunology·2025Open Access
Multiregional CT Features Improve Prediction of Immunotherapy Response in Advanced Melanoma
2025Open Access
Body composition and melanoma incidence risk: insights from a longitudinal lung cancer screening cohort
2025Open Access
Supplementary Figure S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Table S2 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S6 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S5 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Data from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Table S3 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Figure S7 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Methods S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Table S4 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Supplementary Table S1 from Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
2025Open Access
Integrative Immune Signature of Complementary Circulating and Tumoral Biomarkers Maximizes the Predictive Power of Adjuvant Immunotherapeutic Benefits in High-risk Melanoma
Clinical Cancer Research·2025· 1 citedOpen Access
Natural Killer Cell — B Lymphocyte Interactions: The Role of Target Cell Major Histocompatibility Class I Molecules
2024
137 Tertiary lymphoid structure signature in digital H&E slides as a prognostic biomarker in cutaneous melanoma
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
page 1 of 24Next →

Frequent Co-authors

Michael T. Lotze(13), Laurence Zitvogel(8), M T Lotze(6), Hideaki Tahara(6), John M. Kirkwood(6), Paul D. Robbins(6), José Mayordomo(5), Albert B. DeLeo(5), Russell D. Salter(5), Markus Maeurer(5), Robbie B. Mailliard(4), Paweł Kaliński(4), J R Dawson(4), Herbert J. Zeh(4), Tomohide Tatsumi(4), James H. Finke(4), Hideho Okada(4), Martha Clarke(3), Robert D. Schreiber(3), Theresa L. Whiteside(3)